Fosrenol, also known as lanthanum carbonate chewable tablets, is a drug indicated primarily for the treatment of hyperphosphatemia in patients with end-stage renal disease. This drug dissociates in the acidic environment of the upper gastrointestinal tract and binds to phosphate in food to form insoluble lanthanum phosphate complexes to inhibit phosphate absorption, thereby reducing serum phosphate and calcium phosphate levels in the body. To bind phosphate in food more effectively, this drug can be taken with or immediately after a meal. The recommended initial dose of this drug is 750-1500 mg per day, with gradual increases at 2-3 week intervals until the target serum phosphate control value is reached, and it is recommended that patients should take Fosrenol under medical supervision.